Literature DB >> 33670804

Regulation of ZMYND8 to Treat Cancer.

Yun Chen1,2, Ya-Hui Tsai1,2, Sheng-Hong Tseng1,3.   

Abstract

Zinc finger myeloid, nervy, and deformed epidermal autoregulatory factor 1-type containing 8 (Zinc finger MYND-type containing 8, ZMYND8) is a transcription factor, a histone H3-interacting protein, and a putative chromatin reader/effector that plays an essential role in regulating transcription during normal cellular growth. Mutations and altered expression of ZMYND8 are associated with the development and progression of cancer. Increased expression of ZMYND8 is linked to breast, prostate, colorectal, and cervical cancers. It exerts pro-oncogenic effects in breast and prostate cancers, and it promotes angiogenesis in zebrafish, as well as in breast and prostate cancers. In contrast, downregulation of ZMYND8 is also reported in breast, prostate, and nasopharyngeal cancers. ZMYND8 acts as a tumor suppressor in breast and prostate cancers, and it inhibits tumor growth by promoting differentiation; inhibiting proliferation, cell-cycle progression, invasiveness, and metastasis; and maintaining the epithelial phenotype in various types of cancers. These data together suggest that ZMYND8 is important in tumorigenesis; however, the existing data are contradictory. More studies are necessary to clarify the exact role of ZMYND8 in tumorigenesis. In the future, regulation of expression/activity of ZMYND8 and/or its binding partners may become useful in treating cancer.

Entities:  

Keywords:  ZMYND8; epigenetic regulation; pro-oncogenic effects; tumor suppression; tumorigenesis

Mesh:

Substances:

Year:  2021        PMID: 33670804      PMCID: PMC7923094          DOI: 10.3390/molecules26041083

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  39 in total

Review 1.  How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers.

Authors:  Sean D Taverna; Haitao Li; Alexander J Ruthenburg; C David Allis; Dinshaw J Patel
Journal:  Nat Struct Mol Biol       Date:  2007-11-05       Impact factor: 15.369

2.  Selective Recognition of H3.1K36 Dimethylation/H4K16 Acetylation Facilitates the Regulation of All-trans-retinoic Acid (ATRA)-responsive Genes by Putative Chromatin Reader ZMYND8.

Authors:  Santanu Adhikary; Sulagna Sanyal; Moitri Basu; Isha Sengupta; Sabyasachi Sen; Dushyant Kumar Srivastava; Siddhartha Roy; Chandrima Das
Journal:  J Biol Chem       Date:  2015-12-11       Impact factor: 5.157

3.  Suppression of Enhancer Overactivation by a RACK7-Histone Demethylase Complex.

Authors:  Hongjie Shen; Wenqi Xu; Rui Guo; Bowen Rong; Lei Gu; Zhentian Wang; Chenxi He; Lijuan Zheng; Xin Hu; Zhen Hu; Zhi-Ming Shao; Pengyuan Yang; Feizhen Wu; Yujiang Geno Shi; Yang Shi; Fei Lan
Journal:  Cell       Date:  2016-04-07       Impact factor: 41.582

4.  Focal aberrations indicate EYA2 and hsa-miR-375 as oncogene and tumor suppressor in cervical carcinogenesis.

Authors:  Mariska Bierkens; Oscar Krijgsman; Saskia M Wilting; Leontien Bosch; Annelieke Jaspers; Gerrit A Meijer; Chris J L M Meijer; Peter J F Snijders; Bauke Ylstra; Renske D M Steenbergen
Journal:  Genes Chromosomes Cancer       Date:  2012-09-14       Impact factor: 5.006

5.  KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy.

Authors:  Johannes Stein; Michael Majores; Magdalena Rohde; Soyoung Lim; Simon Schneider; Eliana Krappe; Jörg Ellinger; Manfred Dietel; Carsten Stephan; Klaus Jung; Sven Perner; Glen Kristiansen; Jutta Kirfel
Journal:  Am J Pathol       Date:  2014-07-09       Impact factor: 4.307

6.  Serological detection of cutaneous T-cell lymphoma-associated antigens.

Authors:  S Eichmuller; D Usener; R Dummer; A Stein; D Thiel; D Schadendorf
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-09       Impact factor: 11.205

7.  Histone demethylase KDM5A regulates the ZMYND8-NuRD chromatin remodeler to promote DNA repair.

Authors:  Fade Gong; Thomas Clouaire; Marion Aguirrebengoa; Gaëlle Legube; Kyle M Miller
Journal:  J Cell Biol       Date:  2017-06-01       Impact factor: 10.539

8.  Integrative genomic and transcriptomic analysis for pinpointing recurrent alterations of plant homeodomain genes and their clinical significance in breast cancer.

Authors:  Huimei Yu; Yuanyuan Jiang; Lanxin Liu; Wenqi Shan; Xiaofang Chu; Zhe Yang; Zeng-Quan Yang
Journal:  Oncotarget       Date:  2017-02-21

9.  Low expression of ZMYND8 correlates with aggressive features and poor prognosis in nasopharyngeal carcinoma.

Authors:  Jiewei Chen; Jun Liu; Xiaoting Chen; Yong Li; Zizi Li; Chengchao Shen; Keming Chen; Xinke Zhang
Journal:  Cancer Manag Res       Date:  2019-08-21       Impact factor: 3.989

10.  Fusion of ZMYND8 and RELA genes in acute erythroid leukemia.

Authors:  Ioannis Panagopoulos; Francesca Micci; Jim Thorsen; Lisbeth Haugom; Jochen Buechner; Gitte Kerndrup; Anne Tierens; Bernward Zeller; Sverre Heim
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more
  4 in total

1.  Adenosine Receptor A2B Negatively Regulates Cell Migration in Ovarian Carcinoma Cells.

Authors:  Anaí Del Rocío Campos-Contreras; Adriana González-Gallardo; Mauricio Díaz-Muñoz; Francisco G Vázquez-Cuevas
Journal:  Int J Mol Sci       Date:  2022-04-21       Impact factor: 6.208

Review 2.  Protein Degradation by E3 Ubiquitin Ligases in Cancer Stem Cells.

Authors:  Macarena Quiroga; Andrea Rodríguez-Alonso; Gloria Alfonsín; Juan José Escuder Rodríguez; Sara M Breijo; Venancio Chantada; Angélica Figueroa
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

3.  Anticancer Inhibitors.

Authors:  Alessandra Ammazzalorso; Marialuigia Fantacuzzi
Journal:  Molecules       Date:  2022-07-21       Impact factor: 4.927

Review 4.  Functional Roles of Bromodomain Proteins in Cancer.

Authors:  Samuel P Boyson; Cong Gao; Kathleen Quinn; Joseph Boyd; Hana Paculova; Seth Frietze; Karen C Glass
Journal:  Cancers (Basel)       Date:  2021-07-19       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.